274 related articles for article (PubMed ID: 22191802)
1. Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate.
Coyne CP; Jones T; Bear R
Cancer Biother Radiopharm; 2012 Feb; 27(1):41-55. PubMed ID: 22191802
[TBL] [Abstract][Full Text] [Related]
2. Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C
Coyne CP; Jones T; Bear R
Cancer Clin Oncol; 2012 Nov; 1(2):49-80. PubMed ID: 26225190
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma.
Coyne CP; Jones T; Pharr T
Bioorg Med Chem; 2011 Jan; 19(1):67-76. PubMed ID: 21169024
[TBL] [Abstract][Full Text] [Related]
4. Anti-Neoplastic Cytotoxicity of Gemcitabine-(C
Coyne CP; Jones T; Bear R
J Cancer Res Ther Oncol; 2014 Apr; 2(1):. PubMed ID: 25844392
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of Gemcitabine-(C
Coyne CP; Jones T; Bear R
J Cancer Ther; 2012 Oct; 3(5A):689-711. PubMed ID: 26225216
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-(C
Coyne CP; Jones T; Bear R
J Clin Exp Oncol; 2013; 2(2):. PubMed ID: 26251840
[TBL] [Abstract][Full Text] [Related]
7. Epirubicin-[Anti-HER2/
Coyne CP; Jones T; Sygula A; Bailey J; Pinchuk L
J Cancer Ther; 2011 Mar; 2(1):22-39. PubMed ID: 26229727
[TBL] [Abstract][Full Text] [Related]
8. Anti-Neoplastic Cytotoxicity of Gemcitabine-(C
Coyne CP; Jones T; Bear R
Med Chem (Los Angeles); 2013 May; 3(2):210-223. PubMed ID: 26225219
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine.
Coyne CP; Jones T; Bear R
J Cancer Ther; 2015 Jan; 6(1):62-89. PubMed ID: 25821636
[TBL] [Abstract][Full Text] [Related]
10. Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition.
Coyne CP; Ross MK; Bailey JG
J Drug Target; 2009 Jul; 17(6):474-89. PubMed ID: 19480561
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549).
Coyne CP; Narayanan L
Chem Biol Drug Des; 2017 Mar; 89(3):379-399. PubMed ID: 27561602
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549).
Coyne CP; Narayanan L
Drug Des Devel Ther; 2016; 10():2575-97. PubMed ID: 27574398
[TBL] [Abstract][Full Text] [Related]
13. Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu.
Shiu LY; Liang CH; Chang LC; Sheu HM; Tsai EM; Kuo KW
Biosci Rep; 2009 Feb; 29(1):35-45. PubMed ID: 18699774
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine- (C
Coyne CP; Narayanan L
J Pharm Drug Deliv Res; 2015; 4(1):. PubMed ID: 26613088
[TBL] [Abstract][Full Text] [Related]
15. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
17. Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer.
Taucher S; Rudas M; Mader RM; Gnant M; Sporn E; Dubsky P; Roka S; Bachleitner T; Fitzal F; Kandioler D; Wenzel C; Steger GG; Mittlböck M; Jakesz R
Breast Cancer Res Treat; 2003 Dec; 82(3):207-13. PubMed ID: 14703068
[TBL] [Abstract][Full Text] [Related]
18. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.
Ding H; Helguera G; Rodríguez JA; Markman J; Luria-Pérez R; Gangalum P; Portilla-Arias J; Inoue S; Daniels-Wells TR; Black K; Holler E; Penichet ML; Ljubimova JY
J Control Release; 2013 Nov; 171(3):322-9. PubMed ID: 23770212
[TBL] [Abstract][Full Text] [Related]
19. Carnosic Acid, Tangeretin, and Ginkgolide-B Anti-neoplastic Cytotoxicity in Dual Combination with Dexamethasone-[anti-EGFR] in Pulmonary Adenocarcinoma (A549).
Coyne CP; Narayanan L
Anticancer Agents Med Chem; 2019; 19(6):802-819. PubMed ID: 30514195
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.
Song H; Kim TO; Ma SY; Park JH; Choi JH; Kim JH; Kang MS; Bae SK; Kim KH; Kim TH; Seo SK; Choi IW; Song GA; Mortenson ED; Fu YX; Park S
BMC Cancer; 2014 Sep; 14():647. PubMed ID: 25179116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
